Dr Adeola Ayoola is a compassionate medical oncologist, dedicated to achieving the best possible outcome for his patients. He combines clinical research with an active interest in precision oncology using theranostics and genomic markers to deliver personalised treatment plans for those in his care.
Dr Adeola Ayoola is an experienced medical oncologist and molecular imaging specialist at Icon Cancer Centre Townsville and Wesley. He completed his Bachelor of Medicine, Bachelor of Surgery at Obafemi Awolowo College of Health Sciences and commenced post-graduate medical training in the management of acute medical conditions at leading New Zealand and Australian hospitals. Dr Ayoola completed specialist medical oncology training at Calvary Mater Hospital followed by an oncology clinical trials research fellowship at Flinders Centre for Innovation in Cancer, investigating phase I to IV clinical trials. After becoming a Fellow of Royal Australasian College of Physicians (FRACP), he subsequently completed further sub-speciality training in nuclear medicine applications in oncology (molecular imaging and theranostics) at the Royal Brisbane and Women’s Hospital and John Hunter Hospital.
Dr Ayoola maintains a strong interest in education, research and clinical trials, actively engaging in medical student and registrar education through his clinical lecturer position at Macquarie University. He has co-authored several journal articles in leading national and international medical publications and developed clinical oncology protocols for the treatment of neuro-endocrine tumours and chemotherapy-induced diarrhoea. Dr Ayoola is a regular invited speaker at national and international medical conferences to present on molecular imaging and theranostics. He is an alumnus of the London Imperial College Business School where he recently completed his Master of Business Administration, graduating with a Merit.
Dr Ayoola collaborates with other genomic experts to deliver cancer genome analysis; this personalised approach explores other potential treatment modalities based on specific mutations present in those cancer cells. His clinical experience covers a broad range of solid tumour malignancies, with special clinical interest in early phase clinical trials, melanoma, prostate with radioligand therapy (theranostics/PSMA treatment), colon and breast cancers.